FDA Approves MORPHINE SULFATE — Fresenius Kabi, USA LLC

Fresenius Kabi secured FDA approval for its intramuscular morphine sulfate formulation, significantly expanding its therapeutic options within the competitive injectable analgesics market. This launch is projected to bolster the company's revenue stream by capitalizing on the growing demand for diversified pain management therapies.